FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220910411> ?p ?o ?g. }

• W4220910411 endingPage "24" @default.
• W4220910411 startingPage "P1" @default.
• W4220910411 abstract "Abstract Introduction: Triple negative breast cancer (TNBC) is highly heterogeneous, but still most of the patients are treated by the anthracycline/taxane-based neoadjuvant therapy (NACT). Tumor-infiltrating lymphocytes (TILs) are a strong predictive and prognostic biomarker in TNBC, however not always available due to organizational and analytical issues. Peripheral blood counts, which reflect the systemic inflammatory/immune status, are easier to obtain than TILs. We investigated whether baseline white cell or platelet counts, as well as Neutrophil-to-Lymphocyte Ratio (NLR) or Platelet-to-Lymphocyte Ratio (PLR) could replace baseline TILs as predictive or prognostic biomarkers in a series of TNBC treated by standard NACT. Patients and methods: One hundred twenty patients uniformly treated by FEC/taxane NACT in a tertiary cancer care center were retrospectively analyzed. The presence of pathological complete response (pCR: ypT0/Tis, ypN0) or the presence of pCR and small residual disease (ypT0/Tis/T1ab, ypN0) were considered as good responses in data analysis. Baseline/pre-NACT blood count, NLR, PLR and TILs were evaluated as predictors of response, distant recurrence rate and distant recurrence-free survival (DRFS). TILs were assessed on breast tumor biopsies according to the recommendations of the International Immuno-Oncology Biomarker Working Group (www.tilsinbreastcancer.org). Results: TILs ≥30% and ≥1.5% were best predictors of pCR and distant recurrence risk, respectively (p=0.007, p=0.012). However, in this cohort, pCR status was not significantly associated with recurrence. Only the ensemble of patients with pCR and small residual disease had lower recurrence risk and longer survival DRFS (p=0.042, p=0.024, respectively) than the rest of the cohort (larger residual disease). The only parameter which could predict the pCR/small residual disease status was PLR: patients with values lower than 133.25 had significantly higher chance of reaching that status after NACT (p=0.045). However, no direct correlation could be established between baseline PLR and metastatic recurrence. No correlation either was found between TIL and individual blood counts, or between TILs and NLR or PLR. Conclusion: In this cohort, TILs retained their pCR predictive value, however PLR was better predictor of the ensemble of responses which had good outcome in terms of less distant recurrences or longer DRFS (pCR or small residual disease). Thus, baseline PLR is worth further, prospective investigation together with baseline TILs, as it might indicate a good TNBC response to NACT when TILs are unavailable. Citation Format: Nina Radosevic-Robin, Sejdi Lusho, Xavier Durando, Marie-Ange Mouret-Reynier, Myriam Kossai, Nathalie Lacrampe, Ioana Molnar, Frederique Penault-Llorca, Catherine Abrial. Platelet-to-lymphocyte ratio is worth using with tumor-infiltrating lymphocytes to predict good response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-08-24." @default.
• W4220910411 created "2022-04-03" @default.
• W4220910411 creator A5013111190 @default.
• W4220910411 creator A5029086962 @default.
• W4220910411 creator A5030260555 @default.
• W4220910411 creator A5042577208 @default.
• W4220910411 creator A5054491719 @default.
• W4220910411 creator A5061340891 @default.
• W4220910411 creator A5061566268 @default.
• W4220910411 creator A5069540694 @default.
• W4220910411 creator A5084842046 @default.
• W4220910411 date "2022-02-15" @default.
• W4220910411 modified "2023-10-05" @default.
• W4220910411 title "Abstract P1-08-24: Platelet-to-lymphocyte ratio is worth using with tumor-infiltrating lymphocytes to predict good response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients" @default.
• W4220910411 doi "https://doi.org/10.1158/1538-7445.sabcs21-p1-08-24" @default.
• W4220910411 hasPublicationYear "2022" @default.
• W4220910411 type Work @default.
• W4220910411 citedByCount "0" @default.
• W4220910411 crossrefType "journal-article" @default.
• W4220910411 hasAuthorship W4220910411A5013111190 @default.
• W4220910411 hasAuthorship W4220910411A5029086962 @default.
• W4220910411 hasAuthorship W4220910411A5030260555 @default.
• W4220910411 hasAuthorship W4220910411A5042577208 @default.
• W4220910411 hasAuthorship W4220910411A5054491719 @default.
• W4220910411 hasAuthorship W4220910411A5061340891 @default.
• W4220910411 hasAuthorship W4220910411A5061566268 @default.
• W4220910411 hasAuthorship W4220910411A5069540694 @default.
• W4220910411 hasAuthorship W4220910411A5084842046 @default.
• W4220910411 hasConcept C121608353 @default.
• W4220910411 hasConcept C126322002 @default.
• W4220910411 hasConcept C143998085 @default.
• W4220910411 hasConcept C185592680 @default.
• W4220910411 hasConcept C2776802502 @default.
• W4220910411 hasConcept C2777511904 @default.
• W4220910411 hasConcept C2777701055 @default.
• W4220910411 hasConcept C2778292576 @default.
• W4220910411 hasConcept C2778326572 @default.
• W4220910411 hasConcept C2780110267 @default.
• W4220910411 hasConcept C2781197716 @default.
• W4220910411 hasConcept C530470458 @default.
• W4220910411 hasConcept C55493867 @default.
• W4220910411 hasConcept C71924100 @default.
• W4220910411 hasConcept C72563966 @default.
• W4220910411 hasConceptScore W4220910411C121608353 @default.
• W4220910411 hasConceptScore W4220910411C126322002 @default.
• W4220910411 hasConceptScore W4220910411C143998085 @default.
• W4220910411 hasConceptScore W4220910411C185592680 @default.
• W4220910411 hasConceptScore W4220910411C2776802502 @default.
• W4220910411 hasConceptScore W4220910411C2777511904 @default.
• W4220910411 hasConceptScore W4220910411C2777701055 @default.
• W4220910411 hasConceptScore W4220910411C2778292576 @default.
• W4220910411 hasConceptScore W4220910411C2778326572 @default.
• W4220910411 hasConceptScore W4220910411C2780110267 @default.
• W4220910411 hasConceptScore W4220910411C2781197716 @default.
• W4220910411 hasConceptScore W4220910411C530470458 @default.
• W4220910411 hasConceptScore W4220910411C55493867 @default.
• W4220910411 hasConceptScore W4220910411C71924100 @default.
• W4220910411 hasConceptScore W4220910411C72563966 @default.
• W4220910411 hasIssue "4_Supplement" @default.
• W4220910411 hasLocation W42209104111 @default.
• W4220910411 hasOpenAccess W4220910411 @default.
• W4220910411 hasPrimaryLocation W42209104111 @default.
• W4220910411 hasRelatedWork W2013223170 @default.
• W4220910411 hasRelatedWork W2226474804 @default.
• W4220910411 hasRelatedWork W2331329572 @default.
• W4220910411 hasRelatedWork W2368110406 @default.
• W4220910411 hasRelatedWork W2370967127 @default.
• W4220910411 hasRelatedWork W2730977610 @default.
• W4220910411 hasRelatedWork W2783325361 @default.
• W4220910411 hasRelatedWork W2939195303 @default.
• W4220910411 hasRelatedWork W3092369346 @default.
• W4220910411 hasRelatedWork W3166080428 @default.
• W4220910411 hasVolume "82" @default.
• W4220910411 isParatext "false" @default.
• W4220910411 isRetracted "false" @default.
• W4220910411 workType "article" @default.